author-photo

Gloria Iacoboni

Hebron University

9

Papers

74

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (25)
Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

2020 Blood
Show All
- Source
- Cite
- Save
Citations (20)
CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

2019 Blood
Show All
- Source
- Cite
- Save
Citations (12)